S&P 500: One Stock Lords Over More Cash Than Anybody | Investor's Business Daily SPOTLIGHT: Best Mutual Funds 2026 Does Google parent Alphabet (GOOGL) know something everyone else doesn't? The technology giant is sitting on a pile of cash that tops the rest of the S&P 500. Alphabet is holding $126.8 billion in cash, equivalents and short-term investments as of its latest filing. That's more than the $123 billion held by the No. 2 biggest cash hoarder in the S&P 500: Amazon.com (AMZN). X Beating The Market: ...

Elevance Health Inc. (NYSE:ELV) is one of the 15 Best Stocks to Buy According to Billionaire Seth Klarman. Even though Baupost Group has trimmed a stake in Elevance Health Inc. (NYSE:ELV) by 4% during the fourth quarter of 2025, compared to filings for the previous quarter, the holding still represents the fourth-largest position of the fund in the 13F portfolio. It comprises more than 1.2 million shares. Baupost first bought shares in the company at the beginning of 2025. Back then, the stake consisted o ...

Elevance Health, Inc. (NYSE:ELV) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 11, Mizuho analyst Ann Hynes lowered the firm’s price target on Elevance Health, Inc. (NYSE:ELV) from $413 to $350 and maintained a Buy rating on the stock. ​The analyst noted that the reduced price target reflects the company’s reaffirmed guidance amid the ongoing Centers for Medicare and Medicaid Services scrutiny. Hynes said in a research note that the company disclosed that the Cente ...

Core Insights - Elevance Health, Inc. is a significant player in the healthcare industry, focusing on innovative health benefits and services to improve health outcomes for its members [1] - The company is actively competing with other major healthcare providers to maintain its market position [1] Stock Performance - On March 10, 2026, a price target of $350 was set for Elevance Health, indicating a potential upside of approximately 23.81% from its trading price of $282.68 [2][6] - Following the Barclays 28th Annual Global Healthcare Conference, Elevance's stock price increased by 1.31% or $3.66, reflecting positive market sentiment [3] - The stock has shown volatility, trading between $280.92 and $290.55 during the day, with a yearly high of $458.75 and a low of $273.71 [4][6] Market Position - Elevance Health's market capitalization is approximately $62.39 billion, indicating its significant presence in the healthcare industry [5] - The trading volume of 2,496,868 shares on the NYSE suggests strong investor interest and confidence in the company's future prospects [5]

Core Perspective - The article discusses recent developments at Elevance, particularly concerning a letter from the Centers for Medicare & Medicaid Services (CMS) that raises concerns about historical risk adjustment data submission practices prior to April 2023 [1]. Group 1: CMS Sanctions and Concerns - CMS has outlined concerns related to historical risk adjustment data submission practices, indicating that this issue extends beyond mere data submission to a broader policy and payment dispute regarding retroactive corrections under the risk adjustment framework [1]. Group 2: Company Actions - The company has approached the situation with good faith and transparency, indicating a commitment to resolving the issues raised by CMS [2].

Elevance Health (NYSE:ELV) FY Conference Summary Company Overview - **Company**: Elevance Health - **Date of Conference**: March 10, 2026 Key Points CMS Sanctions and Risk Adjustment Practices - **CMS Concerns**: The Centers for Medicare & Medicaid Services (CMS) raised concerns regarding historical risk adjustment data submission practices for services prior to April 2023, indicating a broader policy and payments dispute rather than just a data submission issue [3][4] - **Actions Taken**: Elevance Health has engaged with CMS in good faith, proactively disclosing potentially unverified diagnosis codes and seeking guidance on handling prior year corrections [4][5] - **Current Practices**: The company asserts that its current risk adjustment practices are compliant with CMS regulations and that the issues raised pertain only to historical practices [11][14] - **Financial Impact**: Elevance expects the resolution of this matter will not alter its capital deployment priorities for 2026, maintaining an outlook of at least $5.5 billion in operating cash flow [8][9] Medicare Advantage Business - **2026 Guidance**: The adjusted earnings guidance for 2026 is reaffirmed at a minimum of $25.50 per share, with a benefit expense ratio of approximately 90.2% [16] - **Enrollment Cycle**: A significant portion of the 2026 enrollment cycle is already completed, which helps mitigate in-year financial implications from potential sanctions [10] - **Margin Improvement**: The company anticipates a margin improvement to at least 2% for Medicare Advantage in 2026 [10] Medicaid Trends - **Cost Trends**: Medicaid cost trends have moderated from low double-digit percentages in 2025 to mid-single digits in 2026, driven by changes in acuity and utilization patterns [22][23] - **Operational Initiatives**: Elevance is focusing on tighter medical and pharmacy cost management, expanded behavioral health interventions, and stronger payment integrity to manage costs effectively [24][25] ACA Membership and Effectuation - **Membership Growth**: ACA membership increased by approximately 10% sequentially, with expectations of year-end enrollment at 900,000, down 30% year-over-year [26][30] - **Effectuation Rates**: Effectuation rates for new sales and active renewals are tracking in line with historical patterns, indicating stability in membership activation [26][27] Strategic Direction and Leadership Transition - **Leadership Changes**: The departure of Peter D. Haytaian does not signal a change in strategy for Carelon, which remains integral to Elevance's enterprise strategy [18][19] - **Focus Areas**: The company is prioritizing revenue growth, margin discipline, and enhancing leadership across Carelon's core businesses [19][20] Investment and Technology Initiatives - **Incremental Investments**: Elevance is investing in digital and AI capabilities, scaling Carelon's services, and quality initiatives, with a focus on integrating these technologies across operations [31][32] - **Expected Outcomes**: The company aims for tangible outcomes such as cost reduction, improved cycle times, and productivity gains through these investments [33] Conclusion - **Overall Outlook**: Elevance Health views the CMS sanctions as a historical policy dispute rather than a structural issue affecting its Medicare Advantage business, maintaining confidence in its operational and financial strategies moving forward [15][14]

Core Viewpoint - Elevance Health, Inc. is under investigation for potential securities fraud and unlawful business practices following a notification from the Centers for Medicare & Medicaid Services regarding sanctions on its Medicare Advantage plans [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of Elevance investors, focusing on possible securities fraud or unlawful business practices by the company and its officers [1]. - The investigation was prompted by a recent disclosure from Elevance about sanctions from CMS, which may affect its Medicare Advantage-Prescription Drug plans [2]. Group 2: CMS Sanctions - On March 2, 2026, Elevance announced that CMS intends to impose sanctions that would suspend enrollment of Medicare beneficiaries into its MA-PD plans and halt certain communications with these beneficiaries [2]. - The sanctions are related to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements for services prior to April 3, 2023, and are set to take effect on March 31, 2026, unless resolved [2]. - Following this announcement, Elevance's stock price dropped by $25.93, or 8.1%, closing at $294.07 per share on the same day [2].

Core Insights - Elevance Health and the National Diaper Bank Network have launched a national pilot program aimed at improving diaper affordability and maternal and child health outcomes for families with infants and young children [1] - The 12-month pilot will provide free diapers to up to 75 families per month across 10 communities, potentially reaching 9,000 families in 2026 [1] - The initiative addresses diaper insecurity, which affects nearly one in two U.S. families with young children, and is linked to increased parental stress and adverse health outcomes [1] Program Details - The pilot program will operate in communities including Bakersfield and Los Angeles, California; Hialeah, Florida; Columbia, Missouri; Lakewood, New Jersey; Columbus and Toledo, Ohio; Houston, Texas; and two sites in Washington, D.C. [1] - Families in these communities can access the program through Welcome Rooms operated by Elevance Health affiliated Medicaid health plans [1] Research and Evaluation - The National Diaper Bank Network's Innovation and Impact Department will conduct research to evaluate the relationship between diaper access and key maternal, infant, and child health indicators [1] - Areas of study may include caregiver stress, access to preventive care, financial strain, and connections to additional family support services [1] - Findings from the pilot will inform future investments in integrated approaches to support family well-being [1] Organizational Background - The National Diaper Bank Network, founded in 2011, aims to end diaper insecurity and period product insecurity in the U.S. and has over 300 active member banks [1] - Elevance Health serves over 109 million consumers through a diverse portfolio of healthcare solutions [1]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Elevance Health, Inc. regarding compliance with federal securities laws [1] Group 1: Investigation Details - The investigation is prompted by a disclosure from Elevance on February 27, 2026, indicating that the Centers for Medicare & Medicaid Services intends to impose intermediate sanctions on the company [3] - The sanctions will suspend enrollment into certain Medicare Advantage-Prescription Drug plans and halt communications to Medicare beneficiaries, effective March 31, 2026, unless issues are resolved [3] Group 2: Investor Information - Investors who purchased Elevance securities and experienced losses are encouraged to join the investigation [2][4] - Johnson Fistel offers assistance without any cost or obligation to the investors [2]

Core Viewpoint - The agency intends to suspend enrollment of beneficiaries into specific Medicare Advantage plans, as stated by Elevance [1] Group 1 - The suspension of enrollment will impact certain Medicare Advantage plans offered by Elevance [1]